More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics
The advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, René Bernards discusses why new clinical trial designs are needed and what is being done to achieve this. Such innovative trials can lead to similar outcomes for cancer patie...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13391 |
| _version_ | 1811161237012086784 |
|---|---|
| author | René Bernards |
| author_facet | René Bernards |
| author_sort | René Bernards |
| collection | DOAJ |
| description | The advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, René Bernards discusses why new clinical trial designs are needed and what is being done to achieve this. Such innovative trials can lead to similar outcomes for cancer patients with fewer side effects while at the same time reducing the cost of cancer care. |
| first_indexed | 2024-04-10T06:11:06Z |
| format | Article |
| id | doaj.art-d32eea358caa4ad9a1b94f0378c15e2f |
| institution | Directory Open Access Journal |
| issn | 1574-7891 1878-0261 |
| language | English |
| last_indexed | 2024-04-10T06:11:06Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj.art-d32eea358caa4ad9a1b94f0378c15e2f2023-03-02T15:43:22ZengWileyMolecular Oncology1574-78911878-02612023-03-0117338238310.1002/1878-0261.13391More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeuticsRené Bernards0Division of Molecular Carcinogenesis, Oncode Institute The Netherlands Cancer Institute Amsterdam The NetherlandsThe advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, René Bernards discusses why new clinical trial designs are needed and what is being done to achieve this. Such innovative trials can lead to similar outcomes for cancer patients with fewer side effects while at the same time reducing the cost of cancer care.https://doi.org/10.1002/1878-0261.13391drug developmentphase 1 trialstargeted cancer drugs |
| spellingShingle | René Bernards More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics Molecular Oncology drug development phase 1 trials targeted cancer drugs |
| title | More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics |
| title_full | More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics |
| title_fullStr | More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics |
| title_full_unstemmed | More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics |
| title_short | More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics |
| title_sort | more may not be better reconsidering early clinical trial design in the era of targeted cancer therapeutics |
| topic | drug development phase 1 trials targeted cancer drugs |
| url | https://doi.org/10.1002/1878-0261.13391 |
| work_keys_str_mv | AT renebernards moremaynotbebetterreconsideringearlyclinicaltrialdesignintheeraoftargetedcancertherapeutics |